Sign In
Buy OPY
$99.90
+2.52 (+2.59%)
At Close: Jun 09, 2026
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:27am, Tuesday, 04'th Feb 2025
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the researc
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
07:05am, Tuesday, 04'th Feb 2025
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:00am, Tuesday, 04'th Feb 2025
WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sc
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:00am, Tuesday, 04'th Feb 2025
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
08:00am, Monday, 03'rd Feb 2025
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:30am, Monday, 03'rd Feb 2025
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics f
Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings
08:00am, Friday, 31'st Jan 2025
NEW YORK , Jan. 31, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quar
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
05:00pm, Wednesday, 29'th Jan 2025
Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:14pm, Wednesday, 29'th Jan 2025
PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:00pm, Wednesday, 29'th Jan 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Monday, 27'th Jan 2025
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, anno
XTI Aerospace Adds David Oppenheimer to its Corporate Advisory Board
09:00am, Tuesday, 14'th Jan 2025
ENGLEWOOD, Colo. , Jan. 14, 2025 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace" or the "Company"), a pioneer in VTOL and Powered-Lift aircraft solutions, today announced that Davi
Shake Shack, Darden, Yum! 'Top Picks' for 2025 Says Oppenheimer
03:15pm, Tuesday, 07'th Jan 2025
Olive Garden, KFC, and Shake Shack look like particularly appetizing investments in 2025, according to Oppenheimer analysts.
Oppenheimer Thinks the Stock Market Will Surge 20% in 2025. 1 Stock To Buy Before it Does
01:05pm, Monday, 06'th Jan 2025
It's a new year, and with that, the 2025 S&P 500 forecasts from the big names on Wall Street are in.
Roper Technologies assumed with an Outperform at Oppenheimer
04:49pm, Friday, 20'th Dec 2024
Oppenheimer analyst Ken Wong assumed coverage of Roper Technologies with an Outperform rating and $630 price target. The firm sees potential for revenue acceleration with management targeting companie
